RHEACELL
Stem cell company manufacturing GMP-compliant limbal stem cells from cornea tissue that are ABCB5+, a marker associated with clinical success in transplantation of these cells for treating blindness.
All edits
RHEACEL is a subsidiary of TICEBA, developing human pharmaceuticals based on ABCB5+ mesenchymal stem cells. The company uses the GMP-compliant manufacturing process established by TICEBA to expand primary limbal stem cells from corneal tissue donors. Clinical trials using these cells are ongoing in GermanyGermany and the US.
RHEACEL is a subsidiary of TICEBA, developing human pharmaceuticals based on ABCB5+ mesenchymal stem cells. The company uses the GMP-compliant manufacturing process established by TICEBA to expand primary limbal stem cellslimbal stem cells from corneal tissue donors. Clinical trials using these cells are ongoing in Germany and the US.
RHEACELL
Stem cell company manufacturing GMP-compliant limbal stem cells from cornea tissue that are ABCB5+, a marker associated with clinical success in transplantation of these cells for treating blindness.
RHEACEL is a subsidiary of TICEBA, developing human pharmaceuticals based on ABCB5+ mesenchymal stem cells. The company uses the GMP-compliant manufacturing process established by TICEBA to expand primary limbal stem cells from corneal tissue donors. Clinical trials using these cells are ongoing in Germany and the US.
RHEACELL
Stem cell company manufacturing GMP-compliant limbal stem cells from cornea tissue that are ABCB5+, a marker associated with clinical success in transplantation of these cells for treating blindness.
Find more companies like RHEACELL
